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triaBACKGROUND Most patients with acute coronary syndrome (ACS) are treated with statins, which reduce atherogenic
triglyceride-rich lipoproteins. It is uncertain whether triglycerides predict risk after ACS on a background of statin
treatment.
OBJECTIVES This study examined the relationship of fasting triglyceride levels to outcomes after ACS in patients
treated with statins.
METHODS Long-term and short-term relationships of triglycerides to risk after ACS were examined in the
dal-OUTCOMES trial and atorvastatin arm of the MIRACL (Myocardial Ischemia Reduction with Acute Cholesterol
Lowering) trial, respectively. Analysis of dal-OUTCOMES included 15,817 patients (97% statin-treated) randomly
assigned 4 to 12 weeks after ACS to treatment with dalcetrapib (a cholesteryl ester transfer protein inhibitor) or placebo
and followed for a median 31 months. Analysis of MIRACL included 1,501 patients treated with atorvastatin 80 mg daily
beginning 1 to 4 days after ACS and followed for 16 weeks. Fasting triglycerides at initial random assignment were related
to risk of coronary heart disease death, nonfatal myocardial infarction, stroke, and unstable angina in models adjusted for
age, sex, hypertension, smoking, diabetes, high-density lipoprotein cholesterol, and body mass index.
RESULTS Fasting triglyceride levels were associated with both long-term and short-term risk after ACS. In dal-
OUTCOMES, long-term risk increased across quintiles of baseline triglycerides (p < 0.001). The hazard ratio in the
highest/lowest quintile (>175/#80 mg/dl) was 1.61 (95% conﬁdence interval: 1.34-1.94). There was no interaction of
triglycerides and treatment assignment on the primary outcome. In the atorvastatin group of MIRACL, short-term risk
increased across tertiles of baseline triglycerides (p ¼ 0.03), with a hazard ratio of 1.50 (95% conﬁdence interval: 1.05 to
2.15) in highest/lowest tertiles (>195/#135 mg/dl). The relationship of triglycerides to risk was independent of low-
density lipoprotein cholesterol in both studies.
CONCLUSIONS Among patients with ACS treated effectively with statins, fasting triglycerides predict long-term
and short-term cardiovascular risk. Triglyceride-rich lipoproteins may be an important additional target for therapy.
(A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome;
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2268D espite evidence-based treatmentsincluding intensive statin therapy,patients with acute coronary syn-
drome (ACS) face a high risk of recurrent car-
diovascular events (1–3). The extent to which
this residual risk is attributable to persistent
lipoprotein abnormalities and might be
reduced by additional therapies to modify li-
poproteins remains uncertain.SEE PAGE 2276Lipid interventions after ACS have focused pri-
marily on lowering of low-density lipoprotein choles-
terol (LDL-C) or raising high-density lipoprotein
cholesterol (HDL-C). Triglyceride-rich lipoproteins
comprise a third category of particles that may inﬂu-
ence cardiovascular risk. In particular, the action of
lipases on very low-density lipoprotein (VLDL) and
chylomicrons results in the formation of remnant
particles with increased cholesterol content and po-
tential for atherogenicity (4). Observational cohort
studies andmeta-analyses (5–8) and post-hoc analyses
of trials with ﬁbrates or statins (9–12) suggest that
higher levels of triglyceride-rich lipoproteins correlate
with higher residual risk, although the relationships
are, in some cases, attenuated by adjustment for fac-
tors associated with elevated triglycerides, including
age, hypertension, smoking, diabetes, obesity, and
low HDL-C.
Recent genetic studies support a causal relation-
ship between triglyceride-rich lipoproteins and car-
diovascular risk. In an evaluation of more than 73,000
subjects, investigators from the Copenhagen City
Heart Studies performed Mendelian randomization
analysis of several alleles that affect cholesterol con-
tent of triglyceride-rich lipoproteins, but not HDL-C
or LDL-C (13). By use of the Friedewald formula,
the cholesterol content of triglyceride-rich remnant
lipoproteins was estimated as the portion of total
cholesterol not contained in either LDL or HDL. There
was a strong correlation between the number of al-
leles associated with remnant cholesterol and theSanoﬁ. Dr. Abt is an employee of F. Hoffmann-La Roche, Ltd.
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received March 1, 2015; revised manuscript received March 10, 2incident risk of coronary heart disease. Two recent
large studies demonstrated that polymorphisms of
the gene encoding apolipoprotein C-III that resulted
in lower triglyceride levels were associated with
lower cardiovascular risk (14,15). However, most
subjects included in these genetic analyses were
initially free of cardiovascular disease, few were
treated with a statin, and none had recent ACS.
Although the efﬁcacy of intensive statin therapy
after ACS has been ﬁrmly established in both short-
term and long-term studies (1,3), residual risk re-
mains high despite such treatment (2,16). Statins
reduce triglyceride-rich lipoproteins along with
LDL-C; however, it remains uncertain whether tri-
glycerides predict residual risk after ACS in patients
under effective statin treatment, and thus whether
triglyceride-rich lipoproteins should be a target for
additional therapy. In JELIS (Japan EPA Lipid Inter-
vention Study), eicosapentaenoic acid plus low-dose
statin resulted in an approximately 5% reduction in
triglycerides and a 19% reduction in coronary events,
compared with low-dose statin alone (17). Beneﬁt was
demonstrated in a subgroup of patients with estab-
lished coronary disease, but patients with ACS were
not studied. In the current study, we examined re-
lationships between fasting triglycerides and cardio-
vascular risk after ACS in 2 large trials of patients
treated with statins.
METHODS
The design and principal results of the dal-OUTCOMES
(A Study of RO4607381 in Stable Coronary Heart Dis-
ease Patients With Recent Acute Coronary Syndrome)
and MIRACL (Myocardial Ischemia Reduction with
Aggressive Cholesterol Lowering) trials have been
described previously (1,2,18,19). The institutional re-
view boards at each participating site approved the
studies, and all subjects gave informed consent.
In brief, dal-OUTCOMES was a randomized,
double-blind comparison of the cholesteryl ester
transfer protein inhibitor dalcetrapib with placebo in
15,871 patients with recent ACS (acute myocardialDrs. Bao and DeMicco are employees of Pﬁzer. Drs.
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TABLE 1 Baseline Characteristics of Patients Included From the
dal-OUTCOMES and MIRACL Trials
dal-OUTCOMES
(n ¼ 15,817)
MIRACL
(n ¼ 1,501)
Clinical and demographic characteristics
Age yrs 60  9 65  12
Male 80 66
White race 88 86
Hypertension 67 55
Current smoking 21 28
Diabetes 24 22
Coronary revascularization
before random assignment
91 0
Medications at random assignment
Statins 97 0
Aspirin 97 91
Platelet P2Y12 inhibitor 89 11
Beta-blocker 87 78
ACE inhibitor or ARB 79 49
Values are mean  SD or %.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
MIRACL ¼ Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering.
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2269infarction or unstable angina pectoris). Treatment
began 4 to 12 weeks (median 6 weeks) after ACS and
median follow-up was 31 months. The study was
performed between 2008 and 2012 at 935 sites in 27
countries. Patients were excluded if triglycerides
exceeded 400 mg/dl, but there were no exclusions
on the basis of levels of HDL-C or LDL-C. Evidence-
based statin treatment was advised, although no spe-
ciﬁc statin agent or dose was speciﬁed. In fact, 97% of
patients were treated with a statin at random assign-
ment with a median LDL-C of 73 mg/dl. The primary
outcome measure was a composite of CHD death,
nonfatal myocardial infarction, ischemic stroke, unsta-
ble angina with objective evidence of myocardial ische-
mia requiring urgent re-hospitalization, and cardiac
arrest with resuscitation. The present analysis includes
data from 15,817 patients in both treatment groups who
had a standard fasting lipid proﬁle determined at
random assignment by a central laboratory.
The MIRACL trial was a randomized, double-
blind comparison of atorvastatin 80 mg daily
with placebo in a total of 3,086 patients with ACS
(non–Q-wave acute myocardial infarction or unstable
angina). The study was performed between 1997 and
2000 at 122 sites in 19 countries. Treatment began
24 to 96 h after admission to hospital for ACS and
continued for 16 weeks. Patients with total choles-
terol >270 mg/dl (>7 mmol/l) were excluded, but
there were no exclusions on the basis of LDL-C,
HDL-C, or triglycerides. Patients were excluded if
coronary revascularization had been performed dur-
ing hospitalization for the index ACS event or was
planned or anticipated at the time of random
assignment. The primary endpoint was the composite
of death, nonfatal myocardial infarction, unstable
angina with objective evidence of myocardial
ischemia requiring urgent re-hospitalization, or car-
diac arrest with resuscitation. Fatal or nonfatal stroke
was a secondary endpoint. To align outcome mea-
sures from MIRACL and dal-OUTCOMES for the pre-
sent analysis, the outcome measure from MIRACL
was either a primary study endpoint or stroke. The
present analysis includes data from 1,501 patients in
MIRACL assigned to treatment with atorvastatin 80
mg who had a fasting lipid proﬁle determined at
random assignment. In 1,299 of these patients, a lipid
panel was also measured at 6 weeks of assigned
treatment. In both MIRACL and dal-OUTCOMES,
LDL-C was calculated by the Friedewald formula.
In each trial, hazard ratios were determined for a 10
mg/dl increment in triglycerides at baseline, both in
univariate relationships and in relationships adjusted
for age, sex, history of hypertension, current smok-
ing, diabetes, HDL-C, and body mass index; that is,factors associated with levels of triglycerides. The
distribution of triglyceride levels at baseline was
described in quintiles for dal-OUTCOMES and in
tertiles in MIRACL because of the smaller number of
endpoint events in the latter study. Univariate and
adjusted hazard ratios for occurrence of endpoint
events were determined for each quintile or tertile
of triglycerides, with quintile 1 or tertile 1 serving
as the referent group, and p values for trend
across quintiles or tertiles were determined. In dal-
OUTCOMES, the interaction of triglyceride concen-
tration (as a continuous variable) and treatment
assignment (dalcetrapib or placebo) on risk of an
endpoint was assessed. To determine the interaction
of LDL-C and triglyceride levels on cardiovascular risk,
relationships were examined in patients with LDL-C
above or below the median level at initial random
assignment (73 mg/dl) in dal-OUTCOMES. A value of
p < 0.05 was considered signiﬁcant.
RESULTS
Baseline characteristics of the patients are shown in
Table 1. In dal-OUTCOMES, there were larger pro-
portions of male and hypertensive patients and fewer
current smokers than in MIRACL. Coronary revascu-
larization for the index ACS event was performed
before random assignment in more than 90% of
patients in dal-OUTCOMES but was an exclusion cri-
terion in MIRACL. The use of platelet P2Y12 antago-
nists, b-blockers, and angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers was
FIGURE 1 Risk of Coronary Heart Disease Death, Nonfatal
Myocardial Infarction, Ischemic Stroke, Hospitalization for
Unstable Angina, or Cardiac Arrest With Resuscitation
According to Quintile of Triglycerides Measured at
Initial Random Assignment in the dal-OUTCOMES Trial
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TABLE 2 Triglycerid
Assigned Treatment
At Random Assignment
Triglycerides
Median
Quintile 1
Quintile 2
Quintile 3
Quintile 4
Quintile 5
LDL-C
HDL-C
On Assigned Treatment
Median (IQR)*
Triglycerides
LDL-C
HDL-C
To convert values for trigl
multiply by 0.0259. *Meas
assignment in MIRACL. †p
IQR ¼ interquartile rang
cholesterol; other abbrevia
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2270more frequent in dal-OUTCOMES than in MIRACL.
Prior to random assignment, 97% of patients in
dal-OUTCOMES were treated with a statin, compared
with none in MIRACL.
Table 2 shows lipid levels at random assignment and
on assigned treatment in the 2 trials. In dal-
OUTCOMES, the median triglyceride concentration at
random assignment was 115 mg/dl. On treatment with
dalcetrapib or placebo, triglyceride levels changed
minimally from baseline and remained similar in both
groups (median 111 and 116 mg/dl, respectively).
Consistent with the broad and effective application of
statins, median LDL-C at random assignment was 73
mg/dl and did not change signiﬁcantly after 1 month of
treatment with dalcetrapib or placebo. As expected,
treatment with dalcetrapib raised HDL-C.
In MIRACL, lipid levels at random assignment were
obtained before statin treatment; therefore, median
concentrations of triglycerides (160 mg/dl) and LDL-C
(120 mg/dl) were higher than at random assignment
in dal-OUTCOMES. As expected, 6 weeks of treatment
with atorvastatin 80 mg substantially lowered tri-
glycerides (to a median 110 mg/dl) and LDL-C (to a
median 60 mg/dl).
RELATION OF TRIGLYCERIDE LEVELS TO LONG-TERM
RISK AFTER ACS. During a median 31-month follow-
up period in dal-OUTCOMES, 1,289 patients (8.1%)
had at least 1 primary endpoint event. The risk was
similar in both the dalcetrapib group and the placeboes, LDL-C, and HDL-C (mg/dl) at Initial Random Assignment and on
dal-OUTCOMES (n ¼ 15,817) MIRACL (n ¼ 1,501)
115 Median 160
#80 Tertile 1 #135
>80 to 103 Tertile 2 >135 to 195
>103 to 130 Tertile 3 >195
>130 to 175
>175
Median 73 Median 120
IQR 59–90 IQR 100–144
Median 41 Median 45
IQR 34–48 IQR 38–53
,
dal-OUTCOMES MIRACL
Placebo
(n ¼ 7,679)
Dalcetrapib
(n ¼ 7,657)
Atorvastatin
(n ¼ 1,299)
116 (87–161) 111 (83–157) 110 (80–155)†
74 (59–91) 73 (57–91) 60 (45–76)†
41 (35–49) 52 (43–64)† 44 (37–52)
ycerides to mmol/l, multiply by 0.0113. To convert values for cholesterol to mmol/l,
ured 1 month after random assignment in dal-OUTCOMES and 6 weeks after random
< 0.001 vs. level at random assignment.
e; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein
tions as in Table 1.group (8.3% and 8.0%, respectively). Triglyceride
concentration at random assignment was signiﬁcantly
related to risk. In unadjusted analysis, a 10-mg/dl
increment in triglycerides was associated with hazard
ratio of 1.016 (95% conﬁdence interval [CI]: 1.010 to
1.022; p < 0.001). Adjustment for age, sex, hyperten-
sion, current smoking, diabetes, HDL-C, and body
mass index did not attenuate the relationship (hazard
ratio: 1.018; 95% CI: 1.011 to 1.024; p < 0.001). Risk in-
creased monotonically across quintiles of triglyce-
rides (p < 0.001 for trend) (Figure 1). Relative to the
lowest quintile (#80 mg/dl), risk in the highest quin-
tile of triglycerides (>175 mg/dl) was 1.50 (95% CI:
1.05 to 2.15). There was no signiﬁcant interaction of
treatment assignment (dalcetrapib or placebo) and
triglycerides on the risk of a primary endpoint event
(p ¼ 0.278). The Central Illustration (right panel)
shows Kaplan-Meier analysis by quintile of baseline≤80 >80-103 >103-130 >130-175 >175
B
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Error bars indicate 95% conﬁdence intervals. Lowest quintile is
referent. (A) Univariate relationship. (B) Relationship adjusted
for age, sex, hypertension, current smoking, diabetes, HDL-C,
and body mass index. Adjustment had minimal effect on the
relationship of triglycerides to cardiovascular risk. Relationships
were not signiﬁcantly affected by treatment assignment (dalce-
trapib or placebo). The absolute annualized event rate in lowest
quintile is 2.76%. HDL-C ¼ high-density lipoprotein cholesterol.
CENTRAL ILLUSTRATION Triglycerides and Risk After Acute Coronary Syndrome: Kaplan-Meier Analysis of
Coronary Heart Disease Death, Nonfatal Myocardial Infarction, Ischemic Stroke, Cardiac ArrestWith Resuscitation, or Hospitalization
for Unstable Angina After Acute Coronary Syndrome
Schwartz, G.G. et al. J Am Coll Cardiol. 2015; 65(21):2267–75.
(Left) Short-term cumulative incidence of events according to tertile of triglycerides at initial random assignment in the atorvastatin group of the Myocardial Ischemia
Reduction with Aggressive Cholesterol Lowering trial. Time 0 corresponds to a mean of 63 h after index acute coronary syndrome ACS (range, 24 to 96 h); p ¼ 0.03 for
trend across tertiles. (Right) Long-term cumulative incidence of events according to quintile of triglycerides at initial random assignment in the dal-OUTCOMES trial.
Time 0 corresponds to a median of 6 weeks after index ACS (range, 4 to 12 weeks); p < 0.001 for trend across quintiles. ACS ¼ acute coronary syndrome(s).
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2271triglycerides. The cumulative incidence of endpoint
events diverged according to quintile of triglycerides,
beginning shortly after random assignment and
continuing throughout the observation period. When
baseline LDL-C was dichotomized at its median of 73
mg/dl, signiﬁcant relations between triglycerides and
risk of a primary endpoint event were evident in
both subgroups (p < 0.002) (Figure 2), without signif-
icant interaction of LDL-C and triglycerides on risk
(p ¼ 0.781).
RELATION OF TRIGLYCERIDE LEVELS TO SHORT-TERM
RISK AFTER ACS. In the atorvastatin group of MIR-
ACL, 220 patients (14.7%) with at least one measure-
ment of lipids died or had nonfatal myocardial
infarction, stroke, cardiac arrest, or hospitalization
for unstable angina during the 16 weeks after ACS.
The adjusted hazard ratio associated with a 10 mg/dl
increment in triglycerides at random assignment was
1.014 (95% CI: 0.996 to 1.032); that is, similar to thelong-term hazard ratio in dal-OUTCOMES. Relative to
the lowest tertile (#135 mg/dl), adjusted risk in the
highest tertile of triglycerides (>195 mg/dl) was 1.50
(95% CI: 1.05 to 2.15) (Figure 3). Across the 3 tertiles
of triglycerides, there was a signiﬁcant gradient of
risk (p value for trend ¼ 0.03). Further adjustment
for baseline LDL-C had no effect on this relationship
(p value for trend ¼ 0.03). The cumulative incidence
of endpoint events according to tertile of triglycerides
in the atorvastatin group is shown in the Central
Illustration, left panel. Lipid values were measured
at 1 intermediate time point in MIRACL, at 6 weeks
of assigned treatment. The relationship between tri-
glyceride levels achieved at week 6 and risk of
an endpoint event between week 6 and week 16
was examined. The percentage of patients with an
endpoint event in the lowest tertile of achieved
triglycerides (#90 mg/dl; 2.7%) was less than
that in the upper 2 tertiles (>90 to 135 mg/dl,
FIGURE 2 Risk of Coronary Heart Disease Death, Nonfatal
Myocardial Infarction, Ischemic Stroke, Cardiac Arrest
With Resuscitation, or Hospitalization for Unstable Angina
by Quintiles of Triglycerides Measured at Initial Random
Assignment in the dal-OUTCOMES Trial, Dichotomized at
Median LDL-C at Random Assignment
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Lowest quintile is referent, with absolute annualized event rate
in lowest quintile of 2.76%. N ¼ 15,817. Error bars indicate 95%
conﬁdence intervals. The relationship between triglycerides and
risk of an endpoint event was signiﬁcant (p < 0.002) in each
subgroup of LDL-C. There was no interaction of triglycerides and
LDL-C subgroup on risk of an endpoint event (p ¼ 0.78).
LDL-C ¼ low-density lipoprotein cholesterol.
FIGURE 3 16-Week Risk of Coronary Heart Disease Death,
Nonfatal Myocardial Infarction, Stroke, or Hospitalization
for Unstable Angina According to Tertile of Triglycerides
at Initial Random Assignment to the Atorvastatin 80 mg
group of the MIRACL Trial
2.0
n=1,501; p for trend 0.04
n=1,501; p for trend 0.03
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Tertiles of Triglycerides (mg/dl)
Univariate Relationship
Adjusted Relationship
A
B
Ri
sk
 o
f P
rim
ar
y 
En
dp
oi
nt
 E
ve
nt
(Q
1=
Re
fe
re
nt
)
Ri
sk
 o
f P
rim
ar
y 
En
dp
oi
nt
 E
ve
nt
(Q
1=
Re
fe
re
nt
)
>195
2.0
1.5
1.0
0.5
0.0
≤135 >135-195 >195
(A) Univariate relationship. (B) Relationship adjusted for age,
sex, hypertension, current smoking, diabetes, HDL-C, and body
mass index. Error bars indicate 95% conﬁdence intervals. Lowest
tertile is referent. Absolute risk in the lowest tertile was 12.5%.
MIRACL ¼ Myocardial Ischemia Reduction with Aggressive
Cholesterol Lowering; other abbreviations as in Figure 1.
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22724.4%; >135 mg/dl, 4.0%). However, the total number
of events (45) provided little power and therefore a
test for signiﬁcance was not meaningful.
RELATIONSHIPS OF LDL-C AND HDL-C TO RISK
AFTER ACS. Despite effective use of statins in dal-
OUTCOMES, LDL-C remained strongly related to
long-term risk (Table 3). With adjustment for age, sex,
hypertension, current smoking, diabetes, HDL-C, and
body mass index, a 10 mg/dl increment in LDL-C was
associated with a hazard ratio of 1.083 (95% CI: 1.063 to
1.103; p < 0.001), with a signiﬁcant gradient of risk
across LDL-C quintiles (p < 0.001). In contrast, there
was no relationship of HDL-C to long-term risk in dal-
OUTCOMES (hazard ratio for 10 mg/dl increment:
0.980; 95% CI: 0.931 to 1.031; p ¼ 0.435). Treatment
assignment (dalcetrapib or placebo) had no interaction
with either LDL-C or HDL-C on the risk of a cardiovas-
cular endpoint event. In the atorvastatin group of
MIRACL, baseline LDL-C was unrelated to short-term
(16-week) risk. With adjustment for each of the fac-
tors indicated earlier, risk across LDL-C quintiles was
essentially ﬂat (p ¼ 0.92 for trend). However, a signif-
icant, inverse relation between quintile of HDL-C and
short-term risk after ACS was identiﬁed (p ¼ 0.002).
DISCUSSION
Triglyceride-rich lipoproteins, including denser forms
of VLDL, intermediate-density lipoproteins, and theirremnants, are believed to be atherogenic (4). Statins
not only reduce LDL-C, but also have signiﬁcant
effects to lower concentrations of triglycerides and
of cholesterol contained in triglyceride-rich lipopro-
teins (20).
Despite a background of effective statin treat-
ment, we found a strong, unfavorable relationship of
fasting triglyceride levels to long-term and short-term
prognosis after ACS. The hazard associated with
increasing triglycerides was nearly identical in uni-
variate analysis and after adjustment for risk factors
usually associated with triglyceride levels, including
age, sex, hypertension, smoking, diabetes, HDL-C, and
body mass index, as well as LDL-C. This observation
TABLE 3 Risk of Cardiovascular Events After Acute Coronary Syndrome by Quintile of LDL-C or HDL-C
Quintile LDL-C (mg/dl)
Hazard
Ratio* 95% CI
p Value
for Trend HDL-C (mg/dl) Hazard Ratio* 95% CI
p Value
for Trend
Long-term risk: dal-OUTCOMES trial (n ¼ 15,817)
1 #55 1.00 <0.001 #33 1.00 0.22
2 >55–#67 1.14 0.95–1.37 >33–#38 0.85 0.71–1.01
3 >67–#79 1.12 0.93–1.35 >38–#43 0.90 0.76–1.07
4 >79–#94 1.47 1.23–1.75 >43–#51 0.86 0.73–1.02
5 >94 1.78 1.49–2.13 >51 0.87 0.72–1.08
Short-term risk: MIRACL trial (n ¼ 1,501)
1 <95 1.00 0.92 <36 1.00 0.002
2 95–<113 0.86 0.65–1.15 36–<42 0.76 0.58–0.99
3 113–<130 0.87 0.66–1.15 42–<48 0.79 0.60–1.04
4 130–<152 0.78 0.58–1.04 48–<56 0.74 0.55–0.98
5 >152 1.03 0.78–1.37 >56 0.58 0.43–0.80
*Adjusted for age, sex, hypertension, smoking, diabetes, and body mass index. Analysis by quintile of LDL-C is adjusted for baseline HDL-C. Analysis by quintile of HDL-C is
adjusted for baseline LDL-C. To convert values for cholesterol to mmol/l, multiply by 0.02586.
Abbreviations as in Tables 1 and 2.
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2273suggests that triglyceride-rich lipoproteins may have a
causal relationship to risk after ACS. After adjustment
for conventional risk factors, plasma triglyceride
levels have predicted incident cardiovascular risk in
some (6–8), but not all observational cohort studies (5)
and in patients with stable coronary heart disease
treated with statins (10,12). In patients with unstable
coronary disease, the PROVE-IT TIMI 22 trial showed a
relationship of triglycerides to long-term prognosis
beginning 30 days after ACS on a background of
intensive statin treatment (11). The present analysis
extends these ﬁndings to a much larger cohort of pa-
tients with ACS and indicates that elevated tri-
glycerides, reﬂecting the burden of triglyceride-rich
lipoproteins, are associated with both long-term and
short-term risk after ACS.
In dal-OUTCOMES, long-term risk after ACS was
higher in quintiles 3, 4, and 5 of the triglyceride dis-
tribution, compared with quintile 1. Because the
lower bound of quintile 3 corresponded to a triglyc-
eride concentration of just 105 mg/dl, increased risk
associated with triglyceride rich lipoproteins was
manifest at concentrations that are generally consid-
ered to be normal. In this regard, the present ﬁndings
are consistent with a scientiﬁc statement by the
American Heart Association that optimal fasting tri-
glyceride levels may be <100 mg/dl (21). The incre-
mental long-term cardiovascular risk associated with
a 10-mg/dl increment in triglycerides was similar to
that for a 10-mg/dl increment in LDL-C and was
evident in subgroups either above or below the me-
dian LDL-C of 73 mg/dl. This observation supports the
use of non-HDL-C as a long-term risk indicator
reﬂecting the cholesterol content of both LDL and
triglyceride-rich lipoproteins (22). Treatment witheither dalcetrapib or placebo had no interaction with
triglyceride levels on the risk of a cardiovascular
endpoint event. This observation may be particularly
important and timely with regard to ongoing cardio-
vascular outcomes trials with 2 other compounds in
the same class as dalcetrapib (23). The MIRACL trial
had smaller sample size, shorter observation period,
and fewer endpoint events than dal-OUTCOMES;
nonetheless, elevated triglycerides were associated
with an adverse short-term prognosis after ACS on a
background of treatment with atorvastatin 80 mg
daily. Thus, optimal statin treatment may lower
levels of triglyceride-rich lipoproteins, but does not
abrogate the risk associated with these particles.
STUDY LIMITATIONS. MIRACL and dal-OUTCOMES
were performed approximately 10 years apart. Dur-
ing that interval, standard treatment for ACS evolved
to include more widespread use of early coronary
revascularization and dual antiplatelet therapy.
Nonetheless, the relationships of triglycerides to
risk of recurrent ischemic events were qualitatively
similar in both studies. Baseline triglycerides were
measured in the absence of statin treatment in
MIRACL but on statin treatment in dal-OUTCOMES.
Hence, the distribution of triglyceride levels differed
between the 2 studies, with higher levels in MIRACL.
Both sets of observations are important because a
substantial fraction of patients who present with
ACS are statin-naive (3). Therefore, the relationship
of baseline triglycerides to outcomes observed in
MIRACL (without background statin treatment) and
in dal-OUTCOMES (on statin treatment) each con-
tribute information that may be useful in predicting
clinical risk when a patient presents with ACS. In
both the MIRACL and dal-OUTCOMES studies, a
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Statin
drugs lower LDL-C and cardiovascular risk in survivors
of ACS, but serum triglycerides often remain persis-
tently elevated despite statin treatment. Data from
2 large, randomized trials demonstrate that among
patients with ACS well-treated with statins, triglyc-
eride levels are associated with both short- and long-
term risk of recurrent ischemic events.
TRANSLATIONAL OUTLOOK: It remains uncertain
whether triglyceride-rich lipoproteins are causally
related to residual risk after ACS, and additional
studies should evaluate the efﬁcacy of novel ap-
proaches to triglyceride lowering, including potent
omega-3 fatty acid formulations or modulators of
apolipoprotein CIII.
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2274majority of patients were white and male. Applica-
bility of ﬁndings to other populations is uncertain.
Some studies have indicated a stronger relationship
of triglycerides to incident cardiovascular events in
women (24). Adjustment for diabetes may account for
some of the risk caused by insulin resistance. How-
ever, many nondiabetic patients with ACS are insulin
resistant (25). Therefore, it is possible that insulin
resistance remains an unaccounted variable that
inﬂuenced the relationship between triglycerides
and risk. In both dal-OUTCOMES and MIRACL, base-
line triglycerides were measured under fasting
conditions. Therefore, the present analysis cannot
determine whether post-prandial excursions in tri-
glycerides exert further inﬂuence on risk after ACS,
as has been suggested in some analyses (26). In
dal-OUTCOMES, no interaction was found between
assigned treatment (dalcetrapib or placebo) and tri-
glycerides on risk of an endpoint event; however, it
remains uncertain whether inhibition of cholesteryl
ester transfer protein could affect the atherogenic
potential of hypertriglyceridemia. Triglycerides were
measured in this study, but it is the cholesterol con-
tent of triglyceride-rich remnant lipoproteins that is
believed to confer atherogenicity to these particles.
Research methods are available to measure remnant
lipoprotein cholesterol (4) and may prove useful to
deﬁne risk and determine therapeutic efﬁcacy in
future studies. In the present analyses, LDL-C was
calculated with the use of the Friedewald formula,
which is subject to inaccuracies related to variability
in the actual ratio of triglycerides/VLDL cholesterol
across levels of triglycerides and cholesterol. When
LDL-C was calculated with the use of a nomogram
that takes into account the variability of triglycerides/
VLDL cholesterol (27), there was minimal quantita-
tive and no qualitative impact on the results or con-
clusions (data not shown).
CONCLUSIONS
The present data indicate a strong association of
fasting triglyceride levels with residual risk afterACS in patients receiving effective statin therapy.
However, it remains uncertain whether triglyceride-
rich lipoproteins should be a target of therapy after
ACS, above and beyond statin treatment. The
question will remain open until trials speciﬁcally
test the efﬁcacy of triglyceride-lowering inter-
ventions after ACS. Newer agents, such as potent
omega-3 fatty acid derivatives (28) or antisense
oligonucleotide to apolipoprotein C-III (29), have
the potential to lower triglyceride-rich lipoproteins
dramatically and may provide useful tools to
answer this question in the future. In addition,
antibodies to PCSK9, although primarily intended
to lower LDL-C concentrations, also signiﬁcantly
reduce cholesterol contained in triglyceride-rich li-
poproteins (30).
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